



Arvind Rajpal, PhD

Vice President Large Molecule Drug Discovery - Antibody Engineering & Protein Chemistry, Large Molecule Drug Discovery Genentech

Arvind is vice president of Large Molecule Drug Discovery - Antibody Engineering and Protein Chemistry at Genentech. His research is focused on using protein engineering to modulate the biological mechanisms of diseases. In the past, it has included site-specifically conjugated ADCs, bispecific IgG, and cell therapies in oncology; conditionally activated molecules in cancer immunology and metabolic diseases; patient-derived neutralizing antibodies against infectious pathogens; and directed evolution of alternative scaffolds in neuroscience.

Arvind received his BA in Chemistry and Computer Science from Knox College and his Ph.D. in Chemistry from the University of California at Berkeley. He has worked in biotechnology startups and pharmaceutical companies like Bioren, Rinat-Pfizer and Bristol Myers Squibb. At Genentech, Arvind's group is responsible for discovery, optimization and progression of large molecules, i.e., antibodies, bispecifics, and similar modalities, into clinical development.